0000000000134023

AUTHOR

M. Hoppe-lotichius

showing 3 related works from this author

Liver transplantation for hepatocellular carcinoma--is there a risk of recurrence caused by intraoperative blood salvage autotransfusion?

2011

<i>Background/Aims:</i> The use of intraoperative blood salvage autotransfusion (IBSA) during surgical approaches may contribute to tumour cell dissemination. Therefore, IBSA should be avoided in cases of malignancy. However, the risks of IBSA might be acceptable in liver transplantation (LT) for selected small hepatocellular carcinoma (HCC). <i>Methods:</i> In total, 136 recipients of LT with histologically proven HCC in the explanted liver were included in this analysis. With regard to tumour recurrence, 40 patients receiving IBSA despite HCC (IBSA group) were compared to 96 patients without IBSA (non-IBSA group). <i>Results:</i> Milan criteria as asses…

AdultMalemedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentLiver transplantationMilan criteriaNeoplasm RecurrenceRisk FactorsmedicineCarcinomaHumansAgedSurgical approachIntraoperative blood salvagebusiness.industryOperative Blood SalvageLiver NeoplasmsMiddle Agedmedicine.diseaseNeoplastic Cells CirculatingSurgeryLiver TransplantationHepatocellular carcinomaSurgeryFemaleRadiologyNeoplasm Recurrence LocalbusinessAutotransfusionEuropean surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes
researchProduct

Transarterial Chemoembolization Before Liver Transplantation in 60 Patients With Hepatocellular Carcinoma

2007

Tumor recurrence is a major problem after orthotopic liver transplantation (OLT) in patients with hepatocellular carcinoma (HCC). In 60 patients OLT was performed for HCC after pretreatment by repeated transarterial chemoembolization (TACE). Forty-four recipients exceeded the Milan criteria. Recurrence-free 5-year survival was 65.2% and 5-year freedom from recurrence was 73.2%. During the waiting time, 14 patients experienced minimal change, which did not fulfill the definition of tumor progression according to official oncological criteria. Five-year freedom from recurrence among patients with stable compared with progressive disease was 93.3% versus 28.1%, respectively (P = .0001). A stri…

medicine.medical_specialtyCarcinoma HepatocellularTime Factorsmedicine.medical_treatmentLiver transplantationMilan criteriaGastroenterologyDisease-Free SurvivalRecurrenceInternal medicinePreoperative CaremedicineHumansEmbolizationChemoembolization TherapeuticTransplantationbusiness.industryPatient SelectionLiver Neoplasmsmedicine.diseaseSurvival AnalysisLiver TransplantationSurgeryTransplantationTumor progressionHepatocellular carcinomaSurgerybusinessLiver cancerProgressive diseaseTransplantation Proceedings
researchProduct

Surgical therapy of liver cancer: resection and transplantation

2008

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and is estimated to cause approximately half a million deaths per year. Most tumours (80%) develop in cirrhotic livers caused by viral hepatitis C or B and alcoholic liver disease. In the natural course survival depends on the stage of the disease. At an early stage 3-year survival is 65% without treatment, in the intermediate stage between 10% and 50% of patients are reported to be alive after 2 years, and in the final stage median survival only rarely exceeds 6 months. Surgical treatment is capable of doubling survival. The results of local ablative treatment in early carcinoma are very similar to surgical treatment1…

Oncologymedicine.medical_specialtyAlcoholic liver diseasebusiness.industryCancermedicine.diseaseSurgeryTransplantationLiver diseaseHepatocellular carcinomaInternal medicinemedicineStage (cooking)businessLiver cancerViral hepatitis
researchProduct